Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1552W HIGH $2.88
Volume
1.60 M
Value Traded
45.96 K
Short % Float
1.37%
Days to Cover
1.0
-5.71%Week
-49.11%1 Month
-55.39%3 Month
-82.48%6 Month
-99.01%5 Year
-99.01%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.14 M
EPS (TTM)
-1.59
P/E Ratio
-
Ent. Value
-1.32 M
Total Shares
31.13 M
Float Shares
31.15 M
Insiders
0.00%
Institutions
11.31%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SNTI Catalyst Timeline
Dated clinical, regulatory and corporate events for Senti Biosciences Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Senti Biosciences Holdings, Inc.
185Total events
6Upcoming
34Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseSENTI-202Corporate
Spin-off of SENTI-202 to NewCo with CVR milestone payments up to $60M
▲RMATSENTI-202Designation
SENTI-202 granted Regenerative Medicine Advanced Therapies (RMAT) designation by FDA
relapsed/refractory acute myeloid leukemia (AML)source ↗
▲Full ResultsSENTI-202Clinical Data
Phase 1 trial results: durable MRD-negative responses from 22 patients; composite CR 50% in Donor X subgroup
relapsed/refractory acute myeloid leukemia (AML)source ↗
▲Type B MeetingSENTI-202FDA Meeting
Successful completion of Type B RMAT meeting with FDA
relapsed/refractory acute myeloid leukemiasource ↗
▲FDA Feedback ReceivedSENTI-202FDA Meeting
Positive FDA feedback supports single-arm pivotal trial
Relapsed Refractory Acute Myeloid Leukemia (R R AML)source ↗
▲Biomarker DataSENTI-202Clinical Data
Identified Donor X attribute correlating with efficacy
Relapsed Refractory Acute Myeloid Leukemia (R R AML)source ↗
▲Full ResultsSENTI-202Clinical Data
Durable MRD-negative responses in full 22-patient Phase 1 trial
Relapsed Refractory Acute Myeloid Leukemia (R R AML)source ↗
●Enrollment UpdateSENTI-202Trial
Enrolling adult patients in Phase 1 trial
Relapsed Refractory CD33 and/or FLT3 expressing hematologic malignanciessource ↗
▲Topline ReadoutSENTI-202Clinical Data
Updated Phase 1 clinical data announced
relapsed/refractory acute myeloid leukemiasource ↗
▲Manufacturing MilestoneSENTI-202CMC / Inspection
Donor X phenotype selection for all future manufacturing
relapsed/refractory acute myeloid leukemiasource ↗
◆Oral PresentationSENTI-202Presentation
Educational session at AACR 2026 on Logic-Gated SENTI-202 cell therapy
relapsed/refractory acute myeloid leukemiasource ↗
▲PublicationPresentation
Publication in Cell Systems demonstrating NOT-gated CAR circuits in T and NK cells
▼Equity OfferingCorporate
Entered securities purchase agreement for up to $40 million convertible notes
▲RMATSENTI-202Designation
Received RMAT designation for SENTI-202
relapsed/refractory acute myeloid leukemiasource ↗
▲Topline ReadoutSENTI-202Clinical Data
Updated positive preliminary clinical data from Phase 1 trial of SENTI-202
relapsed/refractory acute myeloid leukemiasource ↗
◆Oral PresentationSENTI-202Presentation
Translational and correlative data presentation at 11th Annual Innate Killer Conference
relapsed/refractory acute myeloid leukemia (AML)source ↗
◆Oral PresentationPresentation
Workshop on biomarker discovery and translational tools for NK therapy at 11th Annual Innate Killer Conference
◆Oral PresentationPresentation
Senti Bio CEO to present at Leerink Partners 2026 Global Healthcare Conference
▲Enrollment CompleteSENTI-202Trial
Completed enrollment in Phase 1 clinical trial of SENTI-202 for R/R AML
relapsed or refractory acute myeloid leukemia (R/R AML)source ↗
◆Oral PresentationPresentation
On-stage company presentation at Healthcare Conference Taipei 2026
▲RMATSENTI-202Designation
FDA granted RMAT designation to SENTI-202
relapsed/refractory hematologic malignancies, including AMLsource ↗
◆Oral PresentationPresentation
Panel presentation at Biotech Showcase 2026: Engineering the Future: Advances in Cell and Gene Therapies
◆Oral PresentationSENTI-202Presentation
Updated clinical results from SENTI-202 presented at ASH Annual Meeting 2025
R/R CD33 and/or FLT3 expressing hematologic malignancies (AML/MDS)source ↗
▲RMATSENTI-202Designation
FDA granted RMAT designation for SENTI-202
relapsed/refractory hematologic malignancies including AMLsource ↗
◆Enrollment UpdateSENTI-202Trial
Enrolling adult patients with R/R CD33 and/or FLT3 expressing heme malignancies
relapsed or refractory Acute Myeloid Leukemiasource ↗
◆Oral PresentationSENTI-202Presentation
Oral presentation of updated clinical data at ASH Annual Meeting 2025
relapsed or refractory acute myeloid leukemiasource ↗
◆Poster PresentationSENTI-202Presentation
Poster presentation of correlative data for SENTI-202 at ASH 2025
Acute Myeloid Leukemia (AML)source ↗
◆Enrollment UpdateSENTI-202Trial
Currently enrolling adult patients in Phase 1 trial
R/R CD33 and/or FLT3 expressing hematologic malignancies (AML/MDS)source ↗
◆Oral PresentationSENTI-202Presentation
Clinical data presentation at ASH Annual Meeting
acute myeloid leukemia (AML)source ↗
◆Oral PresentationPresentation
Senti Bio to present at Chardan's 9th Annual Genetic Medicines Conference
◆Topline ReadoutSENTI-202Clinical Data
Expect to release additional efficacy and durability data from Phase 1 study
acute myeloid leukemia (AML)source ↗
◆Oral PresentationPresentation
Senti Bio to present at H.C. Wainwright 27th Annual Global Investment Conference
◆Oral PresentationPresentation
Presentation at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
◆Oral PresentationSENTI-202Presentation
Senti Bio participates in Virtual Investor segment discussing Phase 2 dose and schedule selection for SENTI-202
relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML)source ↗
▲Dose Finding UpdateSENTI-202Trial
Completed dose finding and confirmed RP2D for SENTI-202
acute myeloid leukemia (AML)source ↗
▲Orphan Drug DesignationSENTI-202Designation
Received Orphan Drug Designation for SENTI-202
acute myeloid leukemia (AML)source ↗
▲Dose Finding UpdateSENTI-202Trial
Recommended Phase 2 Dose (RP2D) determined for SENTI-202
relapsed/refractory hematologic malignancies including acute myeloid leukemiasource ↗
▲Orphan Drug DesignationSENTI-202Designation
FDA granted Orphan Drug Designation for SENTI-202
relapsed refractory hematologic malignancies including AMLsource ↗
▲Orphan Drug DesignationSENTI-202Designation
FDA grants Orphan Drug Designation for SENTI-202
relapsed/refractory hematologic malignancies including AMLsource ↗
▲Topline ReadoutSENTI-202Clinical Data
Positive preliminary results in ongoing Phase 1 trial
relapsed/refractory hematologic malignancies including AMLsource ↗
Past FDA Catalysts and PDUFA Decisions
How SNTI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-24 | SENTI-202-101 (SENTI-202) | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 96%
Micro Cap(rank 631 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SENTI-202 Monoclonal antibodyNCT06325748 | AML/MDS | Phase 1 | ACTIVE NOT_RECRUITING | 21 | Aug 1, 2040 |
Clinical Trial Results
Readouts, endpoints and source filings for every SNTI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SENTI-202 RMATOrphan | Relapsed Refractory Acute Myeloid Leukemia (R R AML) | 2026-05-14 | 50% (7 14) of the patients achieving a composite CR (cCR) when they received any SENTI-202 doses manufactured from Donor X-characteristic derived NK cells in Cycle 1; SENTI-202 continues to achieve durable MRD-negative responses in the full 22 patient Phase 1 trialRead More | Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase Secured strategic financing vehicle for up to $40 million Positive FDA feedback sRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rajangam KanyaOfficer (Pres. & Chief Med. & Dev. Off.) | Disposition | -10,757 74,843 held | $0.00 | 03/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SNTI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| NEA Management Company, LLC | 0.3 % (50 %) | 4.15 M | 3.78 M |
SNTI Institutional Ownership Trends
SNTI Short Interest
Shares sold short, counted twice a month.
1.37%
Short % of Float
of tradable shares sold short
427.4K
Shares Sold Short
-12.3% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
2.0M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SNTI ranks across every disease it competes in
Competitive Position is a premium feature
See how SNTI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSNTI News
-SNTI
Jul 15, 2026▼ -39.7%on this news· ran to -55% by day 3
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform
Senti Biosciences Holdings, Inc. announced a strategic transaction to enhance its focus on controllable genetic medicines via its Regulator Dial technology. This involves a spin-off of its Gene-Circuit-enabled pipeline, including SENTI-202, to a new company controlled by Celadon. The deal includes contingent value rights for future milestone payments tied to SENTI-202's success.
Read more →-SNTI
May 14, 2026▲ +8%on this news
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
Senti Biosciences Holdings announced a positive outcome from a Type B RMAT meeting with the FDA regarding its CAR-NK cell therapy, SENTI-202, aimed at treating relapsed/refractory acute myeloid leukemia (R/R AML). The company plans to conduct a pivotal multi-center trial based on strong Phase 1 results, including the identification of a donor phenotype that optimizes treatment efficacy. As part of their strategy, Senti Bio will utilize cells from donors with this specific phenotype for future manufacturing of SENTI-202. The therapy has demonstrated noteworthy early clinical outcomes, establishing a promising pathway for registration and potential wider use in AML treatment.
Read more →-SNTI
May 14, 2026▲ +8%on this news
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
Senti Biosciences Holdings reported its financial results for Q1 2026, highlighting the advancement of its SENTI-202 program into a pivotal trial for relapsed refractory acute myeloid leukemia (R R AML). The company secured a strategic financing agreement of up to $40 million and received positive feedback from the FDA that supports the study's design. Additionally, Senti reported a significant reduction in both net loss and operational cash burn compared to the same period last year, as they streamline operations and advance clinical strategies. The SENTI-202 product continues to demonstrate potential with durable responses in ongoing trials.
Read more →-SNTI
Apr 13, 2026Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
Senti Biosciences will present its Logic-Gated cell therapies at the AACR Annual Meeting 2026. CEO Timothy Lu will discuss the engineered SENTI-202 therapy and its potential to selectively target cancer cells while sparing healthy ones. The session aims to showcase advancements in oncology and the broader applications of Logic Gates in cancer treatment.
Read more →-SNTI
Apr 1, 2026Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies
Senti Biosciences has published new research in Cell Systems showcasing its innovative NOT-gated CAR circuits, which enhance the precision and safety of cell therapies. The study indicates that these circuits can improve the efficacy of immune cells in targeting tumors while sparing healthy tissue. This research supports Senti's ongoing development of its Gene Circuit platform for cancer treatments.
Read more →-SNTI
Mar 27, 2026▼ -10.4%on this newsshared move
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Senti Biosciences reported its financial results for Q4 and full year 2025, highlighting significant progress in its clinical pipeline, particularly with SENTI-202 for relapsed/refractory AML. The company received RMAT designation from the FDA and reported positive preliminary clinical data. However, it also faced a substantial net loss for the year.
Read more →-SNTI
Mar 23, 2026Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference
Senti Biosciences is set to present clinical and translational data for its SENTI-202 program at the 11th Annual Innate Killer Conference. The Phase I trial focuses on a novel CAR NK cell therapy targeting CD33 and FLT3 in adults with relapsed/refractory acute myeloid leukemia. Presentations will highlight both clinical results and the therapy's unique mechanism of action.
Read more →-SNTI
Mar 3, 2026Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
Senti Biosciences, a clinical-stage biotechnology company, announced that CEO Timothy Lu will present at the Leerink Partners 2026 Global Healthcare Conference in Miami on March 9, 2026. The company focuses on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, which aims to enhance precision in targeting cancer cells. A webcast of the presentation will be available on their website.
Read more →-SNTI
Feb 24, 2026▲ +7.1%on this news
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
Senti Biosciences, a clinical-stage biotech firm, will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CEO Timothy Lu will discuss the company's Gene Circuit technology, pipeline advancements, and partnership opportunities. The event will be available via live webcast, emphasizing Senti's commitment to developing innovative therapies for incurable diseases.
Read more →-SNTI
Feb 20, 2026Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
Senti Biosciences participated in the Cell & Gene Live event, discussing advancements in cell therapy development. The company highlighted its Gene Circuit platform and its product candidate, SENTI-202, designed to target hematologic malignancies. SENTI-202 has received FDA designations for its potential in treating relapsed/refractory conditions. The event facilitated valuable industry discussions on innovative therapeutic solutions.
Read more →-SNTI
Feb 11, 2026Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
Senti Biosciences has completed enrollment in its Phase 1 clinical trial for SENTI-202, a CAR NK cell therapy targeting relapsed or refractory acute myeloid leukemia (R/R AML). The trial showed promising results, including durable complete remissions and a favorable safety profile. The company plans to discuss the next steps with the FDA in 2026, aiming for a pivotal study and potential expansion into newly diagnosed and pediatric AML.
Read more →-SNTI
Feb 3, 2026Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026
Senti Biosciences has been selected for an on-stage presentation at the Healthcare Conference Taipei 2026. CEO Timothy Lu will discuss the company's Gene Circuit technology and its pipeline progress. The presentation is scheduled for February 10, 2026, and aims to attract potential collaborations in the field of cell and gene therapies.
Read more →-SNTI
Jan 14, 2026Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation
Senti Biosciences participated in a Virtual Investor CEO Connect Segment where CEO Timothy Lu discussed the FDA's RMAT designation for SENTI-202, a CAR-NK therapy for relapsed/refractory AML. The company also presented new clinical trial data involving 20 patients at the American Society of Hematology Annual Meeting. This designation builds on the previously granted Orphan Drug Designation.
Read more →-SNTI
Jan 9, 2026Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
Senti Biosciences, Inc. will participate in the Biotech Showcase 2026, with CEO Dr. Timothy Lu as a panelist. The panel will focus on advancements in cell and gene therapies. The event, scheduled for January 12-14, 2026, in San Francisco, serves as a key networking platform for biotech companies and investors.
Read more →-SNTI
Dec 9, 2025▼ -35.6%on this news
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile
Senti Bio reported updated clinical data for SENTI-202 in relapsed or refractory acute myeloid leukemia patients. The therapy achieved a fifty percent overall response rate and a forty-two percent complete remission rate. All complete remissions were minimal residual disease negative. The company also announced FDA Regenerative Medicine Advanced Therapy designation for the treatment.
Read more →-SNTI
Dec 9, 2025▼ -35.6%on this news
Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia
Senti Biosciences has received FDA Regenerative Medicine Advanced Therapy designation for its investigational cell therapy, SENTI-202, aimed at treating relapsed or refractory acute myeloid leukemia (AML). This designation underscores the urgent need for improved therapies in this area and highlights SENTI-202's potential to transform treatment outcomes. The therapy has shown promising clinical results, as presented at the recent ASH Annual Meeting.
Read more →-SNTI
Dec 4, 2025Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET
Senti Bio will host a conference call on December 9, 2025, to discuss updated clinical results for SENTI-202, a CAR-NK cell therapy targeting hematologic malignancies. The call will feature key executives and a hematologist involved in the study. SENTI-202 aims to selectively eliminate cancer cells while protecting healthy bone marrow.
Read more →-SNTI
Nov 13, 2025▼ -10.1%on this news
Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December
Senti Bio reported a net loss of $18.1 million for the third quarter of 2025. The company held $12.2 million in cash and cash equivalents as of September 30. Research and development expenses rose to $10.5 million from $8.7 million in the prior year period. Senti Bio will present updated clinical data for its SENTI-202 study at the American Society of Hematology meeting in December.
Read more →-SNTI
Nov 3, 2025Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025
Senti Bio announced it will present updated clinical results for its SENTI-202 therapy at the ASH Annual Meeting in December 2025. This first-in-class cell therapy targets CD33 and FLT3 in relapsed/refractory acute myeloid leukemia (AML) while protecting healthy cells. The company aims to address the significant unmet need for effective AML treatments.
Read more →-SNTI
Oct 16, 2025▼ -5.6%on this news
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
Senti Biosciences, Inc. announced that CEO Timothy Lu will present at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025, in New York. The company is focused on developing next-generation cell and gene therapies using its Gene Circuit platform. Management will also hold one-on-one meetings with investors during the event.
Read more →About Senti Biosciences Holdings, Inc.
Headquarters2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next SNTI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime